

INVESTOR NEWSLETTER | NOV 2018

BIO-GENE TECHNOLOGY LTD



IN THIS ISSUE

1 - Welcome from Richard Jagger, CEO

2 - Bio-Gene presents at AEPMA 2018 conference

3 - Bio-Gene in the media: Interview with Proactive Investors and Stockhead article

4 - Air traffic, global trade, and managing pests in Australia

5 - Q&A with Dr. James Wade

WELCOME FROM RICHARD JAGGER, CEO

Dear Shareholder,

Welcome to our second investor newsletter, which is being published as we celebrate our one-year anniversary as a listed company on the ASX.

As I reiterated at Bio-Gene's recent AGM in Melbourne, and in our communications throughout 2018, we have had an incredibly busy 12 months progressing the value proposition and proof of concept of our two compounds Flavocide™ and Qcide™, while also engaging with potential partners to discuss collaboration opportunities with our unique technology.

Since our last newsletter in August, Bio-Gene has achieved a number of milestones including commencement of several evaluation discussions with globally prominent companies across a number of our proposed market segments, further positive results in both laboratory and field testing, encouraging toxicology results for Flavocide, and also completion of the latest stage in our development project with CSIRO. A detailed overview of all these items is [available here](#) within our most recent quarterly update.

The response from potential commercial partners to both our Flavocide and Qcide compounds and targeted applications has been highly encouraging, and this was clearly highlighted during my recent travels to Asia, the US and Europe to carry out these discussions. Importantly, these companies have validated the Bio-Gene view of the current needs for new technology in the marketplace, and see the potential for our products to solve some of the problems industry faces today.

As we have noted previously, we expect our research and testing programs to be adapted over time in order to reflect both our company's development plans, as well as the needs of potential partners, and I look forward to providing updates on these activities in due course.

Finally, in October, I had the pleasure of meeting with a number of shareholders and potential investors around Australia as part of a planned roadshow. Overall the discussions were very constructive, with continued interest in the development of our company and milestones ahead.

We appreciate your support of Bio-Gene, and look forward to sharing updates over the coming months.

Sincerely,

Richard Jagger
Chief Executive Officer and Managing Director

BIO-GENE PRESENTS AT AEPMA 2018 CONFERENCE: PEST MANAGEMENT IN A CHANGING MARKET

In September, Bio-Gene's Executive Director R&D Peter May took part in the AEPMA (Australian Environmental Pest Managers Association) bi-annual Conference held on the Gold Coast, chairing several sessions. This year's conference theme was "Pest Management in a Changing Market" with a number of major multinationals in attendance including Bayer, BASF, Syngenta, and Sumitomo.



Bio-Gene's Executive Director R&D Peter May (Pictured)

In addition to learning about new product launches and technologies, the conference was a great networking event for Bio-Gene, and opportunity to discuss both Flavocide and Qcide with industry players.

"It was also productive interacting with large international service companies in attendance such as Rentokil, Flick-Anticimex, and Ecolab, as well as smaller locally based organisations that are a feature of the industry", Mr. May commented.

"An interesting takeaway was that products presented relied heavily on existing chemistry in novel formulations and delivery systems, making it evident there is a huge need for new chemistry such as that offered by Bio-Gene to combat resistance, and ensure ongoing pest-free environments".

For more information on the conference [CLICK HERE](#)



In October, Bio-Gene CEO Richard Jagger sat down with Danielle Doporto from Proactive Investors to talk about the company's Flavocide and Qcide products, upcoming milestones and engagement with potential partners worldwide.

[CLICK HERE](#) to view the interview.



In November, ASX small cap publication Stockhead wrote an article looking at Bio-Gene's technology, the company's commercialisation strategy and the broader team who have been progressing development over the past 12 months. Talking about test data that is of interest to multinationals, CEO Richard Jagger says, "In the middle of this year we took about nine months of data and began introducing ourselves and the technology to global agriculture and chemistry companies around the world. The first thing they validated was our assumption about what the market needed."

[CLICK HERE](#) to read the article

AIR TRAFFIC, GLOBAL TRADE, AND MANAGING PESTS IN AUSTRALIA

An interesting article in the October-November issue of The Australian Cottongrower focused on the growing concern around the introduction of exotic pest species into Australia as a result of increasing air traffic and global trade.

In 2017, Biosecurity Australia stopped more than 340 thousand potential pests and disease-ridden items from entering the country, but guaranteeing the detection of pests at our borders is becoming extremely difficult. Many of these exotic pest species are resistant to currently used chemical groups highlighting the need for insecticide products such as Bio-Gene's Flavocide and Qcide that have a novel mode of action for control of resistant strains

[CLICK HERE](#) to read The Australian Cottongrower article

Exotic species mentioned in the article include major pests in agriculture and public health, such as the Brown marmorated stink bug (*Halyomorpha halys*) which can cause significant damage to key crops including soybeans and corn. Just recently, Australian authorities intercepted a ship bound for New Zealand which was carrying stink bugs on-board, which could have caused billions in damage to food production and overall economy.

[CLICK HERE](#) to read the SMH article on intercepted ship carrying stink bugs





Q&A

DR JAMES WADE, PROGRAM MANAGER

The team at Bio-Gene was recently expanded following the appointment of Dr. James Wade to the role of Program Manager, bringing significant experience from the agribusiness industry including project management, coordination of research collaborations and also carrying out product trials.

Can you tell us about your academic background?

I have a BSc (hons) degree in Biological Science (University of Salford, UK) and Master's degree in Molecular Parasitology and Entomology (University of Manchester, UK). Both these degrees provided me with a strong background into contemporary studies of research into the immunological and molecular aspects of selected parasites and vector/parasite relationships.

A specific emphasis was placed on the epidemiology and control of vectors of known economic importance and their impacts on the public, animal and agricultural sectors. The strong immunological aspect of my Masters studies led me to then undertake my Doctoral (PhD) research in Cell and Developmental Biology at the University of Manchester.

The focus of my PhD degree was the utilisation of the reproductive stem cells (primordial germ cells) of poultry embryos and how these unique cells could be manipulated to help confer resistance to diseases of devastating consequence to the global poultry sector.

Much of your agribusiness career has been spent in the commercial poultry sector, what can you tell us about your work experience in this area?

After completing my PhD studies in 2008, I was initially employed as a Science and Technology Program Manager for a world leading European-based agribusiness holding company (EW-GROUP). In this role I was responsible for a program of collaborative research projects which aimed to improve company process efficiencies.

This often involved cross cultural and geographical collaborations with private industry, leading academic institutions and government organisations. This role saw me coordinate multiple cross disciplinary research projects in order to develop new technologies and methods that would add value to the various businesses under the EW-GROUP umbrella.

In 2015 I took on the role of Research/Technical Development Manager for Aviagen Ltd (an EW-GROUP owned company). Here I was directly responsible to the R&D Director to help lead a broad range of research initiatives aimed at improving the understanding of Aviagen's products, processes, and developing best-practice advice for customers.

I was responsible for the management of the company trials infrastructure, the management, analysis and interpretation of product and research and development trials run in company facilities or in external facilities across Europe. The role involved close collaborations with both internal stakeholders (Technical, R&D and Production arms of the company) as well as with external stakeholders (contractors, researchers and customers). This role delivered multiple research outputs and technical support internally to the company, customer and wider audiences.

“ Bio-Gene immediately struck me as being an ambitious, innovative and forward-thinking company at the start of an exciting new chapter in its development ”

What attracted you to a role with Bio-Gene?

After relocating to Australia from the UK in March 2018 I was keen to utilise skills gained in previous roles as part of a new challenge. Bio-Gene immediately struck me as being an ambitious, innovative and forward-thinking company that was at the start of an exciting new chapter in its development. I was particularly excited at the possibility of being able to utilise the knowledge from my educational background in Parasitology and Entomology in combination with my experience in collaborative research and trial development in order to drive further knowledge of Bio-Gene's unique platform technology. This opportunity was one that I was determined to be a part of, and as such I am extremely proud and delighted to be welcomed into the team.

